Insmed Incorporated (INSM) Appoints Christine Pellizzari as General Counsel and Corporate Secretary
7/29/2013 9:49:41 AM
MONMOUTH JUNCTION, NJ--(Marketwired - July 29, 2013) - Insmed Incorporated (NASDAQ: INSM) a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, today announced the appointment of Christine A. Pellizzari as General Counsel and Corporate Secretary.
Ms. Pellizzari joins Insmed with nearly 20 years of senior-level leadership experience in the global biotechnology and pharmaceutical industry. Prior to joining Insmed, Ms. Pellizzari was with Aegerion Pharmaceuticals, Inc. from 2007 to 2012, where she served as Executive Vice President, General Counsel and Corporate Secretary. Among her accomplishments and responsibilities at Aegerion, Ms. Pellizzari oversaw all the legal aspects of that company's successful IPO and secondary public offering and served as a member of the Executive Management Committee. Prior to that, from 1998 to 2007, Ms. Pellizzari was Senior Vice President, General Counsel and Corporate Secretary at Dendrite, Inc., a Nasdaq-listed, leading provider of sales and marketing solutions to the pharmaceutical industry with over $400 million in annual revenue and more than 2,500 employees in 25 countries that was acquired by Cegedim, S.A. for $750 million in May 2007.
"I am particularly pleased to welcome Christine to the Insmed team. Having worked with Christine while at Aegerion, I know first-hand that she will be an invaluable asset to the Company. Christine has broad legal experience with both development and commercial stage pharmaceutical companies. Her significant leadership experience will provide new insight and valuable perspective as we look to transition the Company to a commercial entity and build Insmed into a leading biopharmaceutical company," said Will Lewis, President and CEO of Insmed.
"It is a pleasure to be joining the Insmed team at this important juncture in the Company's development. The Company's focus on developing new therapeutics for unmet medical needs at the intersection of pulmonary, infectious and orphan diseases offers a very exciting opportunity. I look forward to being a part of this dynamic leadership team as we bring new treatments to patients suffering from these serious lung diseases," commented Ms. Pellizzari.
Before joining Dendrite, Ms. Pellizzari was an Associate in the Corporate and Healthcare Departments at Wilentz, Goldman & Spitzer from 1996 to 1998. From 1994 to 1995, Ms. Pellizzari was a law clerk to the Honorable Reginald Stanton in the Superior Court of New Jersey, Morris and Sussex Vicinages.
Ms. Pellizzari received her Juris Doctor from the University of Colorado School of Law (Boulder, CO) and her Bachelor of Arts in Legal Studies from the University of Massachusetts (Amherst, MA), where she graduated cum laude. Ms. Pellizzari is a member of the New Jersey Bar.
Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKACE®, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections and patients with non-tuberculous mycobacteria (NTM) lung infections. For more information, visit www.insmed.com.
This release contains forward-looking statements. Words, and variations of words, such as "intend," "expect," "will," "anticipate," "believe," "continue," "propose" and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of clinical trials and clinical data, the anticipated benefits of Insmed's products, the anticipated timing of regulatory submissions, and the ability to obtain required regulatory approvals, bring products to market and successfully commercialize products constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of European, Canadian, U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting the Company's product candidates, delays in product development or clinical trials or other studies, patent disputes and other intellectual property developments relating to the Company's product candidates, unexpected regulatory actions, delays or requests, the failure of clinical trials or other studies or results of clinical trials or other studies that do not meet expectations, the fact that subsequent analyses of clinical trial or study data may lead to different (including less favorable) interpretations of trial or study results or may identify important implications of a trial or study that are not reflected in Company's prior disclosures, and the fact that trial or study results or subsequent analyses may be subject to differing interpretations by regulatory agencies, the inability to successfully develop the Company's product candidates or receive necessary regulatory approvals, inability to make product candidates commercially successful, changes in anticipated expenses, changes in the Company's financing requirements or ability raise additional capital, and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012. Investors are cautioned not to place undue reliance on any forward-looking statements that speak only as of the date of this news release. The Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances or changes in its expectations.
Anne Marie Fields
Senior Vice President